FDA approves lapatinib with letrozole for advanced breast cancer.

Monday, February 1st, 2010

MedPage Today (1/31, Fiore) reported, “The FDA has approved a combination of lapatinib (Tykerb) and letrozole (Femara) to treat hormone-positive and HER2-positive advanced breast cancer in postmenopausal women.” The approval was based on “a company-sponsored study that found that women with HER2-positive disease who were taking the combination had survival rates more than double that […]